Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 227

The DOI matches its Crossref record.

Orphandev, French Clinical Trials Network dedicated to Orphan drugs and therapeutics development for rare diseases

Open access
Adjibi, Yolande, Micallef, Joëlle, Blin, Olivier · 2010 · Orphanet Journal of Rare Diseases

Abstract

Though rare diseases affect fewer patients than common diseases, developing drugs for them is subject to the same principles. But constructing and leading rare diseases clinical trials means also facing numerous difficulties which are more important in this field (methodology, little knowledge of the disease’s evolution, choice of the judgment’s criteria, small population’s size, logistical matters...) However during the last decade, France led several initiatives to improve the burden of rare diseases. Centres of Expertise were identified, ability centres have been appointed and a National Plan for rare diseases was developed. Nevertheless, in spite of the great dynamic created by France, development and availability of orphan therapeutics remain problematic regarding rare diseases specificities. In this context, it is important to gather skills and strengths to make patients benefit from fundamental research’s results and accelerate clinical trials. Orphandev is a French Clinical Trials Network based on a strong collaboration principle with all actors involved (academics, industries and patients) dedicated to orphan drugs development. It was created by academics to help academics but also others actors involved in rare diseases’ research. The Network’ skills have already been dedicated to orphan drugs’ trials: Charcot Marie Tooth (2004), Rett (2006) and Progeria (2008). Orphandev has intervened according to the mutualisation and translational research concepts from the experimental phase (in vitro and animals’ tests) to the results’ valorisation with every single actor involved in the study. With the experience gained and the successful results, we have developed an organisational concept in order to capitalise on the lessons learnt and optimise the trials process. In a time of great therapeutics development with solutions coming from gene breakthroughs but not only, Orphandev allows for further improvement of the interface between fundamental research, clinical research and drug developments in rare diseases in a more operational way.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1750-1172-5-s1-p11

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 227

Metadata

Authors
Adjibi, Y., Micallef, J., & Blin, O.
Venue
Orphanet Journal of Rare Diseases
Published
2010-10
Volume
5
Issue
S1
ISSN
1750-1172 (ISSN-L)
OpenAlex
W2031743034
Cited by
227
References
0
FWCI
8.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Orphandev, French Clinical Trials Network dedicated to Orphan drugs and therapeutics development for rare diseases. https://app.cochat.ai/papers/10.1186/1750-1172-5-s1-p11
The paper
Adjibi, Y., Micallef, J., & Blin, O. (2010). Orphandev, French Clinical Trials Network dedicated to Orphan drugs and therapeutics development for rare diseases. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-5-s1-p11

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.